Acquisition by Gilbert Mark John of 12500 shares of Indaptus Therapeutics at 0.33 subject to Rule 16b-3
| INDP Stock | USD 0.46 0.09 24.32% |
Slightly above 55% of Indaptus Therapeutics' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Indaptus Therapeutics stock suggests that some investors are interested at this time. Indaptus Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Indaptus Therapeutics. Many technical investors use Indaptus Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Indaptus Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Indaptus Therapeutics Fundamental Analysis
We analyze Indaptus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Indaptus Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Indaptus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Indaptus Therapeutics stock to make a market-neutral strategy. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics with similar companies.
Peers
Indaptus Therapeutics Related Equities
| FBRX | Forte Biosciences | 7.74 | ||||
| QNRX | Quoin Pharmaceuticals | 3.95 | ||||
| ABVC | ABVC Biopharma | 3.30 | ||||
| LGVN | Longeveron LLC | 2.36 | ||||
| KTTA | Pasithea Therapeutics | 1.39 | ||||
| RZLT | Rezolute | 0.46 | ||||
| TPST | Tempest Therapeutics | 0.84 | ||||
| NTRB | Nutriband | 1.28 | ||||
| KPRX | Kiora Pharmaceuticals | 1.30 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.00 | ||||
| RNXT | RenovoRx | 2.17 | ||||
| REVB | Revelation Biosciences | 2.38 | ||||
| VRAX | Virax Biolabs | 5.00 |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.